echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Lijin biology and methadone cooperate to evaluate the efficacy of keytruda combined with CD137 agonist

    Lijin biology and methadone cooperate to evaluate the efficacy of keytruda combined with CD137 agonist

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Transferred from: Medical Mission Hills < br / > recently, lyvgen announced a clinical trial cooperation agreement with MSD's subsidiaries to evaluate the efficacy of lvgn6051, the second generation 4-1BB (CD137) agonist of lyvgen, and keytruda, the PD-1 inhibitor of MSD, in the treatment of multiple malignant tumors, It includes lung cancer, melanoma, gastrointestinal cancer and lymphoma with high MSI-H or dmmr-h< br / > lvgn6051 is a xlinkab Gamma The bifunctional cross-linked antibody developed by the platform is an active antibody against CD137CD137 is the stimulation signal of immune killing T cellsLvgn6051 combines CD137 and FC γ riib to activate CD137 signal pathway effectively and enhance the effect of cancer immunotherapyDifferent from the first generation CD137 agonist antibody, lvgn6051 has double specificity for CD137 and FC γ riibThe product will start phase 1 clinical trials in 2019 and enter phase 2 clinical trials in 2021< br / > DrWang Jieyi, CEO of Lijin biology, said: "we are pleased to work with MSD to evaluate the combination of keytruda and our innovative 4-1BB (CD137) agonist antibody lvgn6051CD137 signaling provides key support for CD8 + effector T cells in a complementary manner to PD-1 blockadeWe believe that the combination of lvgn6051 and keytruda has the potential to improve the treatment results of patients with advanced cancer, and is expected to expand the application of cancer immunotherapy" < br / > Lijin biology was founded by DrWang Jieyi in 2016, focusing on the research and development of the world's leading combination therapy of tumor immune activating antibody and cancer immune, in order to improve the long-term survival rate of cancer patientsIn July 2018, Lijin biology completed the B round financing of US $30 million< br / > at present, four innovative antibodies have been applied for clinical application in the worldAmong them, anti-PD-1 humanized monoclonal antibody ssi-361 has authorized Anke biology to develop the Chinese market< br / > it is worth mentioning that recently, Lijin biological Suzhou company officially openedAt present, an early R & D and production center with an area of 2000 square meters has been established in Suzhou The company's headquarters, R & D center and GMP workshop are also under active preparation It is reported that the company plans to rapidly establish more than 10 innovative drug pipelines in the next five years < br / > original title: Lijin biology and MSD have reached a cooperation, keytruda combined with CD137 agonist in the treatment of multiple malignant tumors < br / >
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.